全文获取类型
收费全文 | 161313篇 |
免费 | 14436篇 |
国内免费 | 7246篇 |
专业分类
耳鼻咽喉 | 1412篇 |
儿科学 | 3698篇 |
妇产科学 | 2791篇 |
基础医学 | 17615篇 |
口腔科学 | 3390篇 |
临床医学 | 15843篇 |
内科学 | 21528篇 |
皮肤病学 | 2264篇 |
神经病学 | 9870篇 |
特种医学 | 5530篇 |
外国民族医学 | 81篇 |
外科学 | 17032篇 |
综合类 | 27121篇 |
现状与发展 | 30篇 |
预防医学 | 10336篇 |
眼科学 | 3566篇 |
药学 | 13518篇 |
79篇 | |
中国医学 | 5432篇 |
肿瘤学 | 21859篇 |
出版年
2024年 | 446篇 |
2023年 | 2173篇 |
2022年 | 4783篇 |
2021年 | 6225篇 |
2020年 | 5355篇 |
2019年 | 4768篇 |
2018年 | 4607篇 |
2017年 | 5310篇 |
2016年 | 5898篇 |
2015年 | 6030篇 |
2014年 | 10037篇 |
2013年 | 10774篇 |
2012年 | 9900篇 |
2011年 | 10895篇 |
2010年 | 9136篇 |
2009年 | 8768篇 |
2008年 | 8934篇 |
2007年 | 9147篇 |
2006年 | 8217篇 |
2005年 | 7253篇 |
2004年 | 6164篇 |
2003年 | 5253篇 |
2002年 | 4506篇 |
2001年 | 3996篇 |
2000年 | 3335篇 |
1999年 | 2931篇 |
1998年 | 2483篇 |
1997年 | 2229篇 |
1996年 | 1974篇 |
1995年 | 1783篇 |
1994年 | 1507篇 |
1993年 | 1185篇 |
1992年 | 1022篇 |
1991年 | 831篇 |
1990年 | 715篇 |
1989年 | 590篇 |
1988年 | 538篇 |
1987年 | 422篇 |
1986年 | 358篇 |
1985年 | 491篇 |
1984年 | 421篇 |
1983年 | 251篇 |
1982年 | 351篇 |
1981年 | 243篇 |
1980年 | 215篇 |
1979年 | 168篇 |
1978年 | 115篇 |
1977年 | 83篇 |
1976年 | 73篇 |
1975年 | 42篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
71.
Sheng Zhang Yan Wang Jie Xu Bokyung Kim Wenbin Deng Fuzheng Guo 《The Journal of neuroscience》2021,41(2):251
The developing CNS is exposed to physiological hypoxia, under which hypoxia-inducible factor α (HIFα) is stabilized and plays a crucial role in regulating neural development. The cellular and molecular mechanisms of HIFα in developmental myelination remain incompletely understood. A previous concept proposes that HIFα regulates CNS developmental myelination by activating the autocrine Wnt/β-catenin signaling in oligodendrocyte progenitor cells (OPCs). Here, by analyzing a battery of genetic mice of both sexes, we presented in vivo evidence supporting an alternative understanding of oligodendroglial HIFα-regulated developmental myelination. At the cellular level, we found that HIFα was required for developmental myelination by transiently controlling upstream OPC differentiation but not downstream oligodendrocyte maturation and that HIFα dysregulation in OPCs but not oligodendrocytes disturbed normal developmental myelination. We demonstrated that HIFα played a minor, if any, role in regulating canonical Wnt signaling in the oligodendroglial lineage or in the CNS. At the molecular level, blocking autocrine Wnt signaling did not affect HIFα-regulated OPC differentiation and myelination. We further identified HIFα–Sox9 regulatory axis as an underlying molecular mechanism in HIFα-regulated OPC differentiation. Our findings support a concept shift in our mechanistic understanding of HIFα-regulated CNS myelination from the previous Wnt-dependent view to a Wnt-independent one and unveil a previously unappreciated HIFα–Sox9 pathway in regulating OPC differentiation.SIGNIFICANCE STATEMENT Promoting disturbed developmental myelination is a promising option in treating diffuse white matter injury, previously called periventricular leukomalacia, a major form of brain injury affecting premature infants. In the developing CNS, hypoxia-inducible factor α (HIFα) is a key regulator that adapts neural cells to physiological and pathologic hypoxic cues. The role and mechanism of HIFα in oligodendroglial myelination, which is severely disturbed in preterm infants affected with diffuse white matter injury, is incompletely understood. Our findings presented here represent a concept shift in our mechanistic understanding of HIFα-regulated developmental myelination and suggest the potential of intervening with an oligodendroglial HIFα-mediated signaling pathway to mitigate disturbed myelination in premature white matter injury. 相似文献
72.
《Clinical Lymphoma, Myeloma & Leukemia》2020,20(8):e461-e467
IntroductionVon Willebrand factor (vWF) cleaving protease ADAMTS-13 has a key role for maintaining normal size of vWF. A deficiency or dysfunction of vWF cleaving protease is associated with ultra large vWF multimers and thrombotic microangiopathy. Patients with cancers have reduced levels of vWF cleaving protease. In this pilot study, we have evaluated whether or not deficiencies of ADAMTS-13 were present in myelodysplastic syndromes (MDS). Moreover, we assessed if a reduction in basal levels of ADAMTS-13 may play a role in the prognosis of MDS.Patients and MethodsWe measured and compared the levels of vWF cleaving protease ADAMTS-13 in 100 patients with MDS and 35 healthy controls. Patients were divided into 2 groups according to the International Prognostic Scoring System: group I consisting of 44 patients with low-risk MDS and group II of 56 patients with high-risk MDS. Patients with high-risk and low-risk MDS presented significantly lower levels of ADAMTS-13 than controls (P < .001 and P = .0177, respectively). High-risk patients had significantly lower levels of ADAMTS-13 when compared with the low-risk group (P < .001).ResultsWe found that reduced levels of ADAMTS-13 have a relationship with overall survival (P < .001). Statistical analysis showed that ADAMTS-13 correlates with cytogenetics (P < .001) and a tendency of slight correlation with platelet count and basal levels of ADAMTS-13 (R, 0.35; P value, 0.001). Moreover, we found that levels of ADAMTS-13 have correlation with response to treatment (P < .001).ConclusionsADAMTS-13 in MDS might represent a surrogate marker of prognosis, response to therapy, or disease progression. Further studies are needed. 相似文献
73.
74.
Roberto V.P. Ribeiro Mitesh V. Badiwala Danny Ramzy Laura C. Tumiati Vivek Rao 《The Journal of thoracic and cardiovascular surgery》2019,157(2):615-625.e1
Objective
Hypertonic saline (HTS) has potent immune and vascular effects. We assessed recipient pretreatment with HTS on allograft function in a porcine model of heart transplantation and hypothesized that HTS infusion would limit endothelial and left ventricular (LV) dysfunction following transplantation.Methods
Heart transplants were performed after 6 hours of cold ischemic storage. Recipient pigs were randomized to treatment with or without HTS (7.5% NaCl) before cardiopulmonary bypass (CPB). Using a myograft apparatus, coronary artery endothelial-dependent (Edep) and -independent (Eind) relaxation was assessed. LV performance was determined using pressure-volume loop analysis. Pulmonary interleukin (IL)-2, IL-6, and tumor necrosis factor (TNF)-α expression was measured.Results
Weaning from CPB and LV performance after transplantation were improved in HTS-treated animals. Successful weaning from CPB was greater in the HTS-treated hearts (8 of 8 vs 2 of 8; P < .05). Mean LV functional recovery was improved in the HTS-treated animals, as assessed by preload recruitable stroke work (65 ± 10% vs 27 ± 10%; P < .001) and end-systolic elastance (55 ± 7% vs 37 ± 4%; P < .001). Treatment with HTS resulted in improved Edep (mean maximum elastance [Emax], 56 ± 5% vs 37 ± 7%; P < .001) and Eind (mean Emax%, 77 ± 6% vs 52 ± 4%; P < .001) vasorelaxation compared with control. Pulmonary expression of IL-2, IL-6, and TNF-α increased following transplantation, whereas HTS therapy attenuated IL production (P < .001). Transplantation increased plasma TNF-α levels and LV TNF-α expression, whereas HTS prevented this up-regulation (P < .001).Conclusions
Recipient HTS pretreatment preserves allograft vasomotor and LV function, and HTS therapy limits CPB-induced injury. HTS may be a novel recipient intervention to prevent graft dysfunction. 相似文献75.
76.
77.
�� ��a������ٻb��������a��������a������������ �� 《中国实用外科杂志》2019,39(2):194-196
78.
美国胃肠病协会(AGA)于2019年8月在Gastroenterology(《胃肠病学》)杂志上发表了针对胰腺坏死处理的临床实践专家共识的更新,归纳并总结了当前的临床证据与专家意见,旨在为胰腺坏死这一复杂临床情况的最佳干预提供指导建议。近年来,随着临床实践的不断深入,急性胰腺炎胰腺坏死的处理经历了较大的变革。从一开始的以手术为主的清创策略过渡到现阶段较为成熟的升阶梯治疗模式。针对胰腺坏死的治疗主要包含两个方面:非手术治疗和有创干预。其中,非手术治疗主要包括抗菌治疗和营养支持等。一旦坏死组织发生感染或无菌性坏死使病人产生显著临床症状,提示有强烈干预指征时,此时更多地依赖于有创干预。升阶梯治疗模式的主要内容为:以经皮引流或透壁内镜引流为首要手段,对于引流无法处理的大量固体坏死,可进行经皮微创或经内镜下坏死清除,若微创手段干预无效可进行开放手术清创。关于选择经皮微创阶梯治疗还是经内镜阶梯治疗,目前尚无研究显示两者之间对病死率等主要临床结局产生影响,不同治疗中心可根据各中心的专业特长和医疗资源,合理选择治疗方案。 相似文献
79.
80.
Ewelina Kazimierczyk Andrzej Eljaszewicz Paula Zembko Ewa Tarasiuk Malgorzata Rusak Agnieszka Kulczynska-Przybik Marta Lukaszewicz-Zajac Karol Kaminski Barbara Mroczko Maciej Szmitkowski Milena Dabrowska Bozena Sobkowicz Marcin Moniuszko Agnieszka Tycinska 《Pharmacological reports : PR》2019,71(1):73-81